Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Recruiting 2Active not recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3

Conditions

Breast Neoplasms 29HR+/HER2- Advanced Breast Cancer 3Breast Cancer Metastatic 3Squamous Cell Carcinoma of Head and Neck 2Ovarian Neoplasms 2Esophageal Squamous Cell Carcinoma 2Triple Negative Breast Neoplasms 1Solid Tumor 1HR Positive HER2 Negative Advanced Breast Cancer 1HER2-positive Breast Cancer 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasm Female 1Breast Diseases 1Brain Neoplasms 1Advanced HR-positive and HER2-negative Breast Cancer; CDK4/6 Inhibitor Treatment Failed 1Advanced Breast Cancer 1

Interventions

Fulvestrant 6Letrozole 4exemestane 3dalpiciclib 3Trastuzumab 3Docetaxel 3Capecitabine 3Anastrozole 3ribociclib 2palbociclib 2fluzoparib 2apatinib 2Irinotecan 2Gemcitabine 2tusamitamab ravtansine 1trastuzumab deruxtecan 1sacituzumab govitecan 1pyrotinib 1pegfilgrastim 1patritumab deruxtecan 1olaparib 1nirogacestat 1margetuximab 1irinotecan sucrosofate 1abemaciclib 1Zoledronic Acid 1Vinorelbine 1Tamoxifen 1Rogaratinib 1Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Breast Cancer Metastatic × dalpiciclib × Clear all
NCT06612814 2024-09-25

PARP Inhibitor With CDK4/ 6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast Cancer

Fudan University

Phase 3 Active not recruiting
307 enrolled
Breast

Breast Cancer Metastatic

NCT05759546 2024-02-06

PARP Inhibitor With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast Cancer

Fudan University

Phase 2 Recruiting
200 enrolled
Breast

Breast Cancer Metastatic

NCT05759572 2024-02-06

Apatinib With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2- Advanced Breast Cancer

Fudan University

Phase 2 Recruiting
145 enrolled
Breast

Breast Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡